Apexigen Announces Clinical Collaboration On A New Phase 2 Trial For APX005M In Sarcoma
SAN CARLOS, Calif., Dec. 20, 2018 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia University Irving Medical Center.
"We are excited to collaborate on this important new study," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "We believe that combining APX005M with the standard of care could benefit many cancer patients. In conducting this trial we hope that we may advance better I-O treatment options for patients with sarcomas."
Additional information on this trial can be found on the ClinicalTrials.gov website at: NCT03719430.
APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as melanoma, non-small cell lung cancer, pancreatic cancer, esophageal and gastroesophageal junction cancers and renal cell carcinoma in various combinations with immunotherapy, chemotherapy or radiation therapy.
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient's immune system to combat and eradicate cancer. APX005M and Apexigen's additional preclinical programs were discovered using APXiMABTM, Apexigen's proprietary product discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMABTM are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our expectations for the potential benefits of our product candidates, are forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including, but not limited to: Apexigen's early stages of clinical drug development; Apexigen's ability to timely complete clinical trials for its product candidates; Apexigen's ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; and Apexigen's ability to obtain additional capital to finance its operations. In light of these risks, uncertainties and assumptions, these forward-looking events and circumstances are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon any forward-looking statements as predictions of future events. Apexigen does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Apexigen's expectations, except as required by law.
This press release concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.
Vice President, Business Development
View original content to download multimedia:http://www.prnewswire.com/news-releases/apexigen-announces-clinical-collaboration-on-a-new-phase-2-trial-for-apx005m-in-sarcoma-300769282.html
SOURCE Apexigen, Inc.